EMA Authorised: Cystadane (Betaine anhydrous) — Recordati Rare Diseases

View source ↗

Summary

EMA has authorised Cystadane (betaine anhydrous) for homocystinuria, with Recordati Rare Diseases as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homocystinuria

Drugs mentioned

• Cystadane (Betaine anhydrous)

Snippet

Status: Authorised. Therapeutic area: Homocystinuria. MAH: Recordati Rare Diseases. Decision date: 10/12/2024